Skip to main content
Top
Published in: Diabetologia 9/2020

01-09-2020 | Review

Real-world evidence: the devil is in the detail

Authors: Mugdha Gokhale, Til Stürmer, John B. Buse

Published in: Diabetologia | Issue 9/2020

Login to get access

Abstract

Much has been written about real-world evidence (RWE), a concept that offers an understanding of the effects of healthcare interventions using routine clinical data. The reflection of diverse real-world practices is a double-edged sword that makes RWE attractive but also opens doors to several biases that need to be minimised both in the design and analytical phases of non-experimental studies. Additionally, it is critical to ensure that researchers who conduct these studies possess adequate methodological expertise and ability to accurately implement these methods. Critical design elements to be considered should include a clearly defined research question using a causal inference framework, choice of a fit-for-purpose data source, inclusion of new users of a treatment with comparators that are as similar as possible to that group, accurately classifying person-time and deciding censoring approaches. Having taken measures to minimise bias ‘by design’, the next step is to implement appropriate analytical techniques (for example propensity scores) to minimise the remnant potential biases. A clear protocol should be provided at the beginning of the study and a report of the results after, including caveats to consider. We also point the readers to readings on some novel analytical methods as well as newer areas of application of RWE. While there is no one-size-fits-all solution to evaluating RWE studies, we have focused our discussion on key methods and issues commonly encountered in comparative observational cohort studies with the hope that readers are better equipped to evaluate non-experimental studies that they encounter in the future.
Appendix
Available only for authorised users
Literature
23.
go back to reference Rothman KJ, Greenland GS, Lash TL (2008) Modern epidemiology, 3rd edn. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadephlia Rothman KJ, Greenland GS, Lash TL (2008) Modern epidemiology, 3rd edn. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadephlia
24.
go back to reference Petersen I, Douglas I, Whitaker H (2016) Self controlled case series methods: an alternative to standard epidemiological study designs. BMJ 354:i4515CrossRefPubMed Petersen I, Douglas I, Whitaker H (2016) Self controlled case series methods: an alternative to standard epidemiological study designs. BMJ 354:i4515CrossRefPubMed
31.
go back to reference Coggon D, Barker D, Rose G (2009) Epidemiology for the uninitiated, 5th edn. Wiley, New York Coggon D, Barker D, Rose G (2009) Epidemiology for the uninitiated, 5th edn. Wiley, New York
53.
go back to reference Cox E, Martin BC, Van Staa T, Garbe E, Siebert U, Johnson ML (2009) Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report—Part II. Value Health 12(8):1053–1061. https://doi.org/10.1111/j.1524-4733.2009.00601.x CrossRefPubMed Cox E, Martin BC, Van Staa T, Garbe E, Siebert U, Johnson ML (2009) Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report—Part II. Value Health 12(8):1053–1061. https://​doi.​org/​10.​1111/​j.​1524-4733.​2009.​00601.​x CrossRefPubMed
55.
go back to reference Garry E, Buse JB, Gokhale M, Lund JL, Pate V, Sturmer T (2018) Implementation of the prevalent new user study design in the US Medicare population: benefit versus harm. Pharmacoepidemiol Drug Saf 27:167–167 Garry E, Buse JB, Gokhale M, Lund JL, Pate V, Sturmer T (2018) Implementation of the prevalent new user study design in the US Medicare population: benefit versus harm. Pharmacoepidemiol Drug Saf 27:167–167
60.
go back to reference Ryan PB, Buse JB, Schuemie MJ et al (2018) Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab 20(11):2585–2597. https://doi.org/10.1111/dom.13424 CrossRefPubMedPubMedCentral Ryan PB, Buse JB, Schuemie MJ et al (2018) Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab 20(11):2585–2597. https://​doi.​org/​10.​1111/​dom.​13424 CrossRefPubMedPubMedCentral
67.
go back to reference Stürmer T, Schneeweiss S, Brookhart MA, Rothman KJ, Avorn J, Glynn RJ (2005) Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol 161(9):891–898. https://doi.org/10.1093/aje/kwi106 CrossRefPubMed Stürmer T, Schneeweiss S, Brookhart MA, Rothman KJ, Avorn J, Glynn RJ (2005) Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol 161(9):891–898. https://​doi.​org/​10.​1093/​aje/​kwi106 CrossRefPubMed
71.
go back to reference Li F, Thomas LE, Li F (2018) Addressing extreme propensity scores via the overlap weights. Am J Epidemiol 188(1):250–257 Li F, Thomas LE, Li F (2018) Addressing extreme propensity scores via the overlap weights. Am J Epidemiol 188(1):250–257
73.
go back to reference Yoshida K, Solomon DH, Haneuse S et al (2018) Multinomial extension of propensity score trimming methods: a simulation study. Am J Epidemiol 188(3):609–616CrossRefPubMedCentral Yoshida K, Solomon DH, Haneuse S et al (2018) Multinomial extension of propensity score trimming methods: a simulation study. Am J Epidemiol 188(3):609–616CrossRefPubMedCentral
88.
go back to reference Langan SM, Schmidt SA, Wing K et al (2018) The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 363:k3532CrossRefPubMedPubMedCentral Langan SM, Schmidt SA, Wing K et al (2018) The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 363:k3532CrossRefPubMedPubMedCentral
89.
go back to reference Public Policy Committee ISoP (2016) Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf 25(1):2–10CrossRef Public Policy Committee ISoP (2016) Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf 25(1):2–10CrossRef
Metadata
Title
Real-world evidence: the devil is in the detail
Authors
Mugdha Gokhale
Til Stürmer
John B. Buse
Publication date
01-09-2020
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 9/2020
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-020-05217-1

Other articles of this Issue 9/2020

Diabetologia 9/2020 Go to the issue

Up Front

Up front

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine